VYNE Therapeutics (VYNE) Depreciation and Depletion (2025 - 2026)
VYNE Therapeutics (VYNE) posted Depreciation and Depletion of $6000.0 for Q1 2026, little changed on a QoQ basis from $6000.0 in Q2 2025, and little changed year-over-year from $6000.0 in Q1 2025.
VYNE Therapeutics (VYNE) Depreciation and Depletion (2025 - 2026) Analysis & Trends
VYNE Therapeutics' Depreciation and Depletion history runs 2 years deep, the most recent figure standing at $6000.0 for Q1 2026.
- Quarterly Depreciation and Depletion changed 0.0% year-over-year to $6000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18000.0 (changed N/A YoY) and the FY2025 annual result came in at $23000.0, up 475.0% from the prior year.
- Depreciation and Depletion was $6000.0 for Q1 2026 at VYNE Therapeutics, roughly flat from $6000.0 in the prior quarter.
- Across five years, Depreciation and Depletion topped out at $6000.0 in Q1 2025 and bottomed at $6000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 39.39 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 2.20 Mn |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | 6,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6,000.00 |
| Mar 31, 2026 | 6,000.00 |
| Jun 30, 2025 | 6,000.00 |
| Jun 30, 2025 | 6,000.00 |
| Mar 31, 2025 | 6,000.00 |
| Mar 31, 2025 | 6,000.00 |